KRAS and lung cancer: For example, it was recently shown that TRAIL/TRAILR2 signaling increases migration and invasion via a Rac1/PI3K signaling axis in KRAS mutated nonsmall-cell lung cancer and pancreatic ductal adenocarcinomas [24].